Net Revenue

+8% (from 1,196,980k USD in Q3 2024 to 1,291,736k USD in Q3 2025)

Strong underlying demand and market expansion have driven the 8% increase, building on previous period momentum where product mix improvements and geographic expansion efforts began to take hold, resulting in higher overall revenue. " "

Net Income

+22% (from 300,493k USD in Q3 2024 to 365,041k USD in Q3 2025)

Improved operational leverage and cost efficiencies contributed to the 22% rise in net income. The gains reflect not only revenue growth but also the benefits of prior period cost discipline and restructuring initiatives that have now translated into stronger profitability. " "

Operating Income

+14% (from 374,586k USD in Q3 2024 to 426,269k USD in Q3 2025)

Enhanced margin expansion and disciplined expense management have resulted in a 14% increase. The current period benefits from improved gross margins and cost controls that built on trends from the previous period, driving operating income higher. " "

Diluted EPS

+21% (from 2.04 USD in Q3 2024 to 2.48 USD in Q3 2025)

Higher earnings per share were achieved due to the amplified net income growth, potentially aided by share repurchase activities or a lower share count. This improvement is consistent with the enhanced profitability trends established in the prior period. " "

Net Cash Provided by Operating Activities

+44% (from 402,031k USD in Q3 2024 to 578,661k USD in Q3 2025)

Significant improvement in cash conversion efficiency, driven by better working capital management and higher earnings, helped operating cash flow surge by 44%. This enhancement builds on previous period strategies that reduced cash outflows and improved customer payment inflows. " "

Effective Tax Rate

FY 2025

19% to 21% "

19% to 21% "

no change

Gross Margin

Q4 FY 2025

no prior guidance

Broadly consistent with 59.9% "

no prior guidance

SG&A Expenses

Remainder of FY 2025

no prior guidance

18% to 20% of revenue "

no prior guidance

R&D Expenses

Remainder of FY 2025

no prior guidance

6% to 7% of revenue "

no prior guidance

Share Buyback Program

Q4 FY 2025

no prior guidance

Approximately $100 million per quarter "

no prior guidance

Gross Margin Expansion & Operational Efficiency

Previously, Q2 2025, Q1 2025 and Q4 2024 calls detailed robust improvements in gross margins (e.g. increases of 230–330 bps) driven by manufacturing/logistics efficiencies, procurement initiatives, and product mix improvements. " " "

In Q3 2025, gross margin expanded by 140 basis points to 59.9% amid continued emphasis on operational efficiency via manufacturing/logistics improvements, cost-recovery through process upgrades, and sustained long‐term initiatives. " "

Consistent focus: The company continues to tighten operational efficiency and margin improvement initiatives, with refined execution as seen in the sustained margin upgrades.

Device Sales Growth & Demand Generation

Prior periods (Q2, Q1, Q4 2024) emphasized strong, often double-digit global device sales growth with supportive demand generation via traditional channels, digital platforms, and international market expansion. " " "

Q3 2025 maintains robust global device sales growth (7% increase on constant currency) and underscores further investment in demand generation through direct-to-consumer campaigns, physician education, and technological innovations such as data-driven segmentation. " "

Sustained and Evolving: While growth remains strong, there is an evolving emphasis on innovative, technology-enabled demand generation and targeted outreach.

Digital Health Transformation & Consumer Wearable Trends

In previous quarters (Q2, Q1, Q4 2024) the discussion centered on building a digital health ecosystem with cloud‐connected devices, AI integration, and initial partnerships with consumer tech companies to enhance patient engagement. " " "

In Q3 2025, the company reaffirms its commitment by expanding its digital health ecosystem with advanced AI, machine learning, and a “digital sleep health concierge” concept, further integrating wearables (e.g. NightOwl and VPAP Tx) to drive diagnosis-to-therapy pathways. " "

Intensified focus: The digital health strategy is deepening and expanding, reflecting a broader ecosystem integration and augmented capabilities via consumer wearables.

Supply Chain Challenges, Freight Costs & Tariff Exemption Dependency

Earlier calls (Q2, Q1, Q4 2024) addressed navigating broad supply chain challenges, with discussions on mitigating freight costs (e.g. shifts between air and sea freight) and stable tariff exemptions protecting margins. " "

Q3 2025 highlights improved freight cost efficiencies—sea freight ratios approaching pre-COVID levels—and reaffirms resilient tariff exemptions, demonstrating effective supply chain management through operational resilience. " " "

Improved and stable: The company is successfully managing logistics costs and maintaining tariff advantages, with a continual focus on cost optimization in the supply chain.

Competitive Dynamics & Pricing Environment

Q1, Q2 and Q4 2024 discussions included competitive positioning against peers (e.g. Philips), price adjustments to offset cost pressures, and leveraging digital tools to maintain pricing power and volume growth. " " "

Q3 2025 did not provide explicit commentary on competitive dynamics or pricing; the focus was more on operational and efficiency improvements rather than on altering competitive pricing strategies.

Not explicitly addressed: While previous periods tackled competitive positioning and pricing adjustments, Q3 2025 did not spotlight these, suggesting either continued stability or a strategic pause in commentary.

Sleep Lab Backlogs & Diagnostic Conversion Challenges

In Q2 2025, there was an acknowledgment that in‑lab sleep labs were facing capacity constraints, prompting moves toward scaling home sleep testing through products like NightOwl, although Q1 and Q4 2024 had limited or no explicit mentions.

Q3 2025 offers detailed discussion on sleep lab backlogs and outlines how technologies like NightOwl and VPAP Tx are being leveraged to reduce bottlenecks and improve diagnostic conversion metrics (e.g. time to titration, test, therapy onset). " "

Emerging emphasis: The focus on alleviating sleep lab bottlenecks through innovative home testing represents a growing and strategically important area, enhancing diagnostic throughput.

Strategic Tuck-in Acquisitions

Q1, Q2, and Q4 2024 calls described a consistent strategy of pursuing smaller acquisitions (often sub-5% of market cap) that reinforce their digital and sleep health capabilities, citing examples like Snap Technologies and Somnoware. " "

In Q3 2025, the commitment to strategic tuck-in acquisitions remains, with continued evaluation of opportunities that align closely with their 2030 vision and provide both cultural and financial returns, though no new deals were announced. "

Consistently integrated: The focus on strategic, smaller-scale acquisitions remains a key part of the company’s long-term growth strategy, with steady, if discreet, activity.

Mask Resupply & Subscription Models

Previous periods (Q1, Q2, Q4 2024) highlighted strong growth in mask and accessories sales driven by resupply programs (Brightree, Snap) and innovative subscription models, especially in both traditional and cash pay markets. " " "

Q3 2025 reiterates the importance of mask resupply programs, emphasizing efficient outreach, adherence improvements, and the role of digital platforms in ensuring patients receive new, clean masks, thereby supporting long-term patient outcomes. "

Stable with continuous optimization: The resupply and subscription models continue to drive adherence and sales growth, with incremental improvements and a consistent global rollout strategy.

Pharmaceutical Megatrends & GLP-1 Weight Loss Drug Opportunities

Across Q1, Q2, and Q4 2024, discussions centered on how GLP-1 medications are creating new channels for patient engagement and therapy adherence, supported by real-world data analyses demonstrating improved PAP initiation and adherence. " " "

In Q3 2025, ResMed continued to leverage GLP-1 trends, noting high adherence among patients on combined CGP and PAP therapy, and emphasizing the role of educational initiatives (e.g., CME) to further capture emerging demand. " "

Sustained and strategically important: The focus on pharmaceutical megatrends, especially around GLP-1 drugs, remains robust, underpinning long-term growth by expanding patient engagement and adherence.

Inventory Management & Working Capital Concerns

Prior calls (Q4 2024, Q1, Q2 2025) discussed managing rising inventory levels driven by freight cost strategies and efforts to reduce working capital, with improvements noted over the last 12 months and through active supply chain adjustments. " "

Q3 2025 briefly noted strong operating cash flow of $472 million (excluding a tax refund) with lower working capital, indicating continued effective management without new concerns. "

Consistently well-managed: The company has effectively stabilized inventory levels and improved working capital, reflecting ongoing operational discipline without emerging concerns.